# Cancer Cell Biology and Signaling

> **NIH NIH P30** · THOMAS JEFFERSON UNIVERSITY · 2021 · $50,997

## Abstract

CANCER CELL BIOLOGY AND SIGNALING PROGRAM (CCBS)
ABSTRACT: The purpose of CCBS, a Discipline-Based Program, is to make fundamental mechanistic
discoveries into signaling pathways that are dysregulated in human cancer and to translate findings into
new treatment opportunities. Common themes are to: 1) Integrate genomic, biochemical and functional
analyses to determine the role and dysregulation of signaling pathways in relevant cancer models; 2)
Identify mechanisms of resistance to targeted inhibitors; and 3) Characterize the role of the stroma in the
tumor microenvironment. Current specific aims are:
Aim 1: Discover mechanisms regulating cell growth & metastasis by heterotrimeric and monomeric
GTPases
Aim 2: Characterize the role of the tumor microenvironment in regulating protein kinase signaling
 pathways and metabolism
Aim 3: Identify the regulation and role of inflammation and cytokine signaling
The CCBS Program has 42 members that include basic scientists, clinical researchers, and population
scientists that have made high-impact discoveries at the bench and in the clinic. Members generated 776
publications, an increase of +19.4% over the prior project period. Of these, 135(17.4%) were intra-
programmatic, an increase of +58.2%; 164 were inter-programmatic (21.1%). Overall impact has improved
with 7.5% appearing in journals with an impact factor >10 and an average impact factor of 5.6. In 2016,
SKCC also began to track collaborations with authors from other NCI-designated Cancer Centers; at
present, 34.2% of CCBS Program publications were in collaboration with authors from other NCI-designated
Centers. The overall impact of CCBS is illustrated by the number of high-impact fundamental discoveries
that have been published in the last funding cycle, including in Cell, PNAS, JAMA, J. Clin Invest., J. Clin
Oncol., Nature and Nature Comm.
In the last funding period, CCBS members were productive in securing funding. Notably, the mechanism for
calculating total and direct costs has changed since the last CCSG review, now requiring exclusion of
funding sources that were allowable in the last review. Furthermore, SKCC was last reviewed during the
peak of ARRA funding. Despite these barriers in comparing current funding totals versus the last review,
CCBS remains strong. Total cancer relevant funding increased from $13.7M to $17.1M total costs (+29.0 %)
with direct costs also increasing from $9.4M to $12.2 (+29.8%). Annual peer-reviewed funding is steady
from the last review at $11.7M total/ $7.7M direct, with 27.2 % of peer-reviewed funding derived from NCI,
and 32.8% from combined federal cancer-dedicated peer review sources (NCI + Department of Defense
Cancer Programs).

## Key facts

- **NIH application ID:** 10173662
- **Project number:** 5P30CA056036-22
- **Recipient organization:** THOMAS JEFFERSON UNIVERSITY
- **Principal Investigator:** Andrew Eric Aplin
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $50,997
- **Award type:** 5
- **Project period:** 1995-06-22 → 2023-05-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10173662

## Citation

> US National Institutes of Health, RePORTER application 10173662, Cancer Cell Biology and Signaling (5P30CA056036-22). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/10173662. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*